Drug intelligence / Profile preview

NCX006

Development stage: Preclinical
Lead developer: TiumBio
Modality: Small Molecules

Overview

NCX006 is a small molecule anti-fibrotic therapeutic under development by TiumBio. It is being investigated primarily for the treatment of fibrotic diseases, with early research focused on hepatic fibrosis and idiopathic pulmonary fibrosis. The precise mechanism of action has not been defined or disclosed publicly as of the latest updates. NCX006 is considered a new molecular entity and does not have orphan drug status[1][2].

Beyond the preview

Go deeper on NCX006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCX006.

Explore the full profile